Detalhe da pesquisa
1.
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.
J Heart Lung Transplant
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38852934
2.
Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study.
J Heart Lung Transplant
; 41(3): 411-420, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34848133